Kevin Rudi Superhero 5K Fun Run to raise money for sarcoma research

What
The second annual Kevin Rudi Superhero 5K Fun Run will start and end by the Memorial Stadium Field House in Las Cruces. Money raised for sarcoma research will benefit The University of New Mexico Comprehensive Cancer Center.

Why
Kevin Rudi passed away November 12, 2014, from spindle cell sarcoma. He was 27. His New Mexico State University fraternity brothers started a foundation to honor his memory and to raise money for sarcoma research.

For Matthew Duran and the rest of the Kevin Rudi Foundation board of directors, the decision to use the superhero theme for their 5K fundraising run was easy. "He's my superhero," says Duran. Duran and Rudi were inseparable best friends in college and remained close until Rudi's passing. "The guy didn't give up," Duran says. "He never gave up. He fought till his last day."

The inaugural 5K Superhero Rudi Fun Run was held May 2, 2015, and raised more than $15,000. Almost 150 people ran and many more donated. This year, organizers expect more than 200 registered runners. Everyone is welcome.

Runners may register the day of the event for $30. Superhero costumes are strongly encouraged.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients